Matthew Taylor
Stock Analyst at Jefferies
(3.44)
# 916
Out of 4,862 analysts
174
Total ratings
61.32%
Success rate
11.54%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $135 → $137 | $135.62 | +1.02% | 13 | Apr 17, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $13.36 | +12.28% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $72.25 | +42.56% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $75.15 | -6.85% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $304.63 | -26.80% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $87.27 | -12.91% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.48 | +4,940.32% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $161.20 | -24.94% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $3.09 | +353.07% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $20.77 | +116.71% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.50 | -0.36% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.16 | +335.86% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $8.19 | +193.22% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $377.30 | -8.56% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $91.28 | +42.42% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $256.50 | -10.33% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $17.42 | +14.81% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $53.55 | +58.73% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $58.90 | +27.33% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $249.34 | -1.74% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $30.62 | +102.48% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $119.93 | +75.10% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $11.06 | +8.55% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $81.99 | +52.46% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $99.74 | -49.87% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $512.18 | -59.00% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $45.70 | +110.07% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.30 | +204.35% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $172.21 | +54.46% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $10.66 | +50.09% | 2 | Jul 19, 2017 |
Abbott Laboratories
Apr 17, 2025
Maintains: Hold
Price Target: $135 → $137
Current: $135.62
Upside: +1.02%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $13.36
Upside: +12.28%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $72.25
Upside: +42.56%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $75.15
Upside: -6.85%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $304.63
Upside: -26.80%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $87.27
Upside: -12.91%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.48
Upside: +4,940.32%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $161.20
Upside: -24.94%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $3.09
Upside: +353.07%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $20.77
Upside: +116.71%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.50
Upside: -0.36%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.16
Upside: +335.86%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $8.19
Upside: +193.22%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $377.30
Upside: -8.56%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $91.28
Upside: +42.42%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $256.50
Upside: -10.33%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $17.42
Upside: +14.81%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $53.55
Upside: +58.73%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $58.90
Upside: +27.33%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $249.34
Upside: -1.74%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $30.62
Upside: +102.48%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $119.93
Upside: +75.10%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $11.06
Upside: +8.55%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $81.99
Upside: +52.46%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $99.74
Upside: -49.87%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $512.18
Upside: -59.00%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $45.70
Upside: +110.07%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.30
Upside: +204.35%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $172.21
Upside: +54.46%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $10.66
Upside: +50.09%